Incidence of Proliferative Diabetic Retinopathy and Other Neovascular Sequelae at 5 Years Following Diagnosis of Type 2 Diabetes
Research Design and Methods: Insured patients aged ≥18 years with newly diagnosed type 2 diabetes and 5 years of continuous enrollment were identified from a nationwide commercial claims database containing data from 2007 to 2015. The incidences of PDR, TRD, and NVG were computed at 5 years following the index diagnosis of type 2 diabetes. Associations between these outcomes and demographic, socioeconomic, and medical factors were tested with multivariable logistic regression.
Examining Primary Care Physician Rationale for not Following Geriatric Choosing Wisely Recommendations
Why do physicians order tests or treatments in older adults contrary to published recommendations?
Schaeffer Solutions: Reining in Prescription Drug Costs
Through sophisticated and rigorous analysis of drug costs, the Schaeffer Center created an evidence-based playbook for federal and state policymakers to tackle distortions in the drug distribution system.
Schaeffer Solutions: Developing Innovative Payment Models for Prescription Drugs
Innovative payment models, like the Netflix model, expand access for vulnerable populations while reducing costs and preserving incentives to innovate.
USC-Brookings Schaeffer Initiative for Health Policy Year 5 Report 2020
The USC-Brookings Schaeffer Initiative for Health Policy aims to produce high-quality, high-impact research and develop innovative policy solutions to the most pressing health care challenges. During the COVID-19 pandemic, the Initiative’s work and expertise have been valuable to policymakers trying to address the COVID crisis and those seeking to understand new laws mandating free coverage…
Gestational Diabetes Rates During Pregnancy on the Rise
Pregnant women in California are, like Thulien, increasingly facing a gestational diabetes diagnosis. The disorder’s unrelenting ascent has alarmed medical providers, and spurred a range of efforts to address the problem.
Association Between Exenatide Use and Incidence of Alzheimer’s Disease
Exenatide use is associated with a reduced incidence of AD among Medicare beneficiaries aged 65 years or older with type II diabetes.
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for advances in Alzheimer’s disease made in 2001 and projects future breakthroughs over the next 20 years.
In the Era of COVID-19, States Need Practical Solutions to Address Health Care Costs
Recent analyses by multiple think tanks indicate that tens of millions of Americans could lose their employer-sponsored health coverage.
It’s Hard to Lower Drug Prices, If You Don’t Know What They Are
In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
CBO Estimate on Pelosi Drug Bill Misses its Long-Term Impact on Health
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
State Drug Pricing Transparency Laws: Numerous Efforts, Most Fall Short
166 recently enacted prescription drug pricing laws were analyzed to identify those that contained price transparency measures. Of these, 35 bills in 22 states include a transparency component, but only 7 were deemed to be informative.
Medicaid Expansion Increases Access to Diabetes Medications
States that expanded Medicaid saw a 40 percent increase in prescription fills for common diabetes drugs in 2014-2015 according to the study in Health Affairs.
Medicaid Eligibility Expansions May Address Gaps In Access To Diabetes Medications
The researchers find Medicaid eligibility expansions are linked to increases in prescription fills for diabetes drugs.
Is Investing in Research to Delay Aging of Value Today?
The time is ripe for a new frontier in medicine.
Follow the Money: The Flow of Funds in the Pharmaceutical Distribution System
Any government intervention to control drug pricing should be predicated on a clear understanding of the economic forces that drive price increases, and the parties responsible for them.
Flow of Money Through the Pharmaceutical Distribution System
For every $100 spent at retail pharmacies, about $17 compensates for direct production costs, $41 accrues to the manufacturer, and $41 accrues to intermediaries in the distribution system.
Schaeffer Center Panel Divides Over Prospect of Medicare Drug Price Negotiation
The debate is increasingly focused on the tradeoff between innovation and access.
Why Risk Adjustment is a Crucial Component of Individual Market Reform
In order to mitigate incentives for insurance companies to avoid sicker patients, policymakers will need to include a risk adjustment program in any replacement reforms that require insurers to issue insurance to any applicant and set limits on adjusting premiums to fully reflect an enrollee’s health status.
Innovations in Patient Care are Key to Improving Outcomes, National Leaders Find
Pharmacists who could help those at risk are underutilized by health systems, USC professor says
- ← Previous
- 1
- 2
- 3
- 4
- Next →